Technical Analysis for NTII - Neurobiolgl Tech Inc

Grade Last Price % Change Price Change
C 0.008 3900.00% 0.0078
NTII closed up 3900.0 percent on Monday, October 18, 2021, on 41 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical NTII trend table...

Date Alert Name Type % Chg
Crossed Above 200 DMA Bullish 0.00%
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Gapped Up Strength 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3900.00%
Narrow Range Bar Range Contraction 3900.00%
Wide Bands Range Expansion 3900.00%
Older End-of-Day Signals for NTII ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Neurobiolgl Tech Inc Description

Neurobiological Technologies, Inc. (NTI), was previously focused on developing investigational drugs to treat human diseases. On October 27, 2009, the Company’s stockholders approved the dissolution of the Company pursuant to a plan of complete liquidation and dissolution earlier approved by its board of directors on August 27, 2009 (the Plan of Dissolution). As a Company in dissolution, NTI was not allowed to carry on any business except for the purpose of winding down the business and affairs of the Company. On December 17, 2009, the Company filed a certificate of dissolution with the Secretary of State of the State of Delaware (the Certificate of Dissolution). As of June 30, 2010, NTI retains an interest in an investigational drug called XERECEPT, which is a synthetic preparation of Corticotropin-Releasing Factor, a natural human peptide. XERECEPT is being developed by Celtic Pharma as a treatment for swelling around brain tumors and other cancer indications.


Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Business Law Board Of Directors Brain Tumor Human Disease Insolvency Liquidation Corporate Law Human Diseases Brain Tumors Swelling

Is NTII a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News


Indicator Value
52 Week High 0.09
52 Week Low 0.0001
Average Volume 32,684
200-Day Moving Average 0.0060
50-Day Moving Average 0.0069
20-Day Moving Average 0.0007
10-Day Moving Average 0.0010
Average True Range 0.0019
ADX 12.94
+DI 58.5062
-DI 32.7801
Chandelier Exit (Long, 3 ATRs) 0.0023
Chandelier Exit (Short, 3 ATRs) 0.0058
Upper Bollinger Bands 0.0042
Lower Bollinger Band -0.0028
Percent B (%b) 1.54
BandWidth 1000.0000
MACD Line -0.0013
MACD Signal Line -0.0020
MACD Histogram 0.0008
Fundamentals Value
Market Cap 216.16 Thousand
Num Shares 27 Million
EPS 0.69
Price-to-Earnings (P/E) Ratio 0.01
Price-to-Sales 0.07
Price-to-Book 0.07
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0080
Resistance 3 (R3) 0.0080 0.0080 0.0080
Resistance 2 (R2) 0.0080 0.0080 0.0080 0.0080
Resistance 1 (R1) 0.0080 0.0080 0.0080 0.0080 0.0080
Pivot Point 0.0080 0.0080 0.0080 0.0080 0.0080
Support 1 (S1) 0.0080 0.0080 0.0080 0.0080 0.0080
Support 2 (S2) 0.0080 0.0080 0.0080 0.0080
Support 3 (S3) 0.0080 0.0080 0.0080
Support 4 (S4) 0.0080